drugset
drugset / Trial / NCT05594992

An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in MPS II (Hunter Syndrome) Subjects

NCT05594992 ↗

Phase 3 Enrolling by invitation 80 enrolled JCR Pharmaceuticals Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

An extension of Global Phase III open-label, multicenter designed to evaluate the Long-term safety and efficacy of study drug for the treatment of the MPS II.

Timeline

Start
2023-02-22
Primary completion
2028-02-28
Completion
2028-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject PABINAFUSP ALFA Protein / enzyme biologic 2 mg/kg Intravenous

Indications

mucopolysaccharidosis type 2